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Retroperitoneal ﬁbrosis (RPF) is a rare disease characterized by the presence of
ﬁbroinﬂammatory tissue around the abdominal aorta and ureteral entrapment in most
cases. Idiopathic RPF is frequently reported in association with autoimmune diseases;
however, there have been few reports of idiopathic RPF associated with Hashimoto's
thyroiditis. Here, we report a case of idiopathic RPF with Hashimoto's thyroiditis in a
patient with a single functioning kidney, which was successfully treated by corticos-
teroid therapy and transient intraureteral stent insertion with a double-J catheter.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Retroperitoneal ﬁbrosis (RPF) is a rare disease with an
unclear etiology and is characterized by chronic nonspeciﬁc
inﬂammation of the retroperitoneum. The hallmark of this
disease and its main complication is ureteral entrapment,
which is often silent and progressive [1,2]. Several studies
have noted that patients with idiopathic RPF are more likely to
suffer from other autoimmune diseases such as autoimmune
pancreatitis or Riedel's thyroiditis [3,4]. However, there have
been few reports of cases of idiopathic RPF associated with
Hashimoto's thyroiditis, particularly in patients with a single
functioning kidney. In this report, we describe the case of
idiopathic RPF in a Hashimoto's thyroiditis patient with a
single functioning kidney, which was successfully with corti-
costeroid therapy and transient intraureteral stent insertion
using a double-J catheter.n Society of Nephrology. Publi
c-nd/4.0/).
y, Department of Internal
hwasan-dong, Wansan-gu,Case report
A 73-year-old Korean woman presented to our outpatient
clinic with a complaint of right ﬂank pain for the past 2 days.
She had a 5-year history of hypertension and was taking a
calcium channel blocker and a beta-blocker. On admission, her
blood pressure was 150/80 mmHg. Her lower extremities
showed grade 1 pretibial pitting edema.
Chest radiograph images showed no abnormalities. Both
kidneys showed elevated renal parenchymal echogenicity and
small size (right kidney, 8.5 4.4 cm; left kidney, 6.5 
3.1 cm; Fig. 1). In addition, her right kidney showed hydrone-
phrosis. Her blood urea nitrogen and serum creatinine concen-
trations were 10.4 mmol/L (reference value: 2.8–7.1 mmol/L) and
282.9 µmol/L (53-106 µmol/L), respectively; 2 weeks earlier, her
serum creatinine concentration had been 150.3 µmol/L. The
patient's urinary protein excretion was 0.4 g/day. Her hemoglo-
bin concentration was 82 g/L (140-175 g/L) and her serum
protein level was 66 g/L (60-80 g/L). The serum concentration
of C-reactive protein was 78.6 nmol/L (0.76-28.5 nmol/L). Her
thyrotropin, triiodothyronine, and free thyroxine levels were
128.42 mIU/mL (0.3–4.0 mIU/mL), 0.01 nmol/L (0.92–2.76 nmol/L),
and 5.53 pmol/L (12–30 pmol/L), respectively. Her anti-
thyroglobulin antibody and anti-microsomal antibody titers wereshed by Elsevier. This is an open access article under the CC BY-NC-ND
Figure 1. Renal ultrasonography. Both kidneys show increased renal parenchymal echogenicity and decreased size: right kidney, 8.5 cm4.4 cm;
left kidney, 6.5 cm 3.1 cm.
Figure 2. Computed Tomography before and after treatment. (A) Abdominal computed tomography (CT) scan results revealed a diffuse inﬁltrating
mass extending from the lower pole of the kidney to the aortic bifurcation level, as well as ureteral obstruction and moderate hydronephrotic and
hydroureteric changes on both sides (arrows). (B) The retroperitoneal mass almost disappeared at the follow-up abdominal CT scan.
Figure 3. Renography with Tc-99m diethylenetriamine pentaacetate.
The function of left kidney was impaired in comparison with the right
kidney (5.8% vs. 94.2%).
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(0–60 IU/mL), respectively.
Hydronephrosis was suspected and the patient underwent an
abdominal computed tomography (CT) scan. The scan revealed a
diffuse inﬁltrating mass extending from the lower pole of the
right kidney to the level of the aortic bifurcation and right
ureteral obstruction, as well as moderate hydronephrotic and
hydroureteric changes on both sides (Fig. 2A). We diagnosed the
patient with postrenal acute renal failure and underlying chronic
kidney disease and performed an ultrasonography-guided per-
cutaneous nephrostomy. After percutaneous nephrostomy and
consecutive double-J stent insertion, her right ﬂank pain resolved
and her serum creatinine level improved to 114.4 µmol/L. She
underwent Tc-99m diethylenetriamine pentaacetate renography,
which revealed the function of the left kidney to be impaired
relative to that of the right (5.8% vs. 94.2%; Fig. 3). To evaluate the
underlying cause of her RPF, the patient underwent positron
emission tomography combined with CT, which yielded no
additional speciﬁc ﬁnding except for low attenuation with
hypermetabolic activity in both lobes of the thyroid gland.
Oral administration of prednisolone (0.5 mg/kg) and
levothyroxine (0.1 mg/day) was initiated on Day 18 of
hospitalization on the basis of the presumptive diagnosis
of RPF associated with Hashimoto's thyroiditis. After
1 month of steroid and levothyroxine therapy, her thyroid
function had recovered to normal levels and a follow-up
abdominal CT scan revealed that the retroperitoneal mass
almost disappeared (Fig. 2B). The double-J catheter was
removed 3 months later. The dose of corticosteroid was
tapered to 6 mg/day during the next 6 months. At the 9-
month follow-up visit, the patient's serum creatinine level
was 106.8 µmol/L.Discussion
We herein presented a case of idiopathic RPF associated with
Hashimoto's thyroiditis in a patient with a single functioning
kidney. The patient's serum creatinine level returned to the
baseline level after ureteral decompression and corticosteroid
treatment. Her thyroid function also became normal after treat-
ment with levothyroxine.
Although idiopathic RPF has been reported in association
with autoimmune disorders, there have been few reports of
idiopathic RPF associated with autoimmune thyroiditis [3–5].
Most reports of idiopathic RPF in combination with chronic
thyroiditis involved cases of Riedel's thyroiditis, in which the
thyroid gland is replaced by ﬁbrous tissue [5,6]. A previous
study reported that 30% of patients with Riedel's thyroiditis
subsequently developed idiopathic RPF [6]. In our case, the
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tions of autoimmune antibodies, which together were sugges-
tive of Hashimoto's thyroiditis [7]. Levothyroxine treatment had
restored her thyroid function to normal, as noted during her 1-
month follow-up examination.
The patient's renogram showed impaired function of the
atrophied left kidney, which was attributed to RPF. Moreover,
her serum creatinine increased rapidly from 150.3 to 282.9 µmol/L
in just 2 weeks. Patients with an atrophied kidney may be
predisposed to develop renal dysfunction rapidly if aggravated
idiopathic RPF causes hydronephrosis of the functional contral-
ateral kidney. Our patient's renal function improved after percu-
taneous nephrostomy. Therefore, percutaneous nephrostomy and
consecutive double-J stent insertion should be considered in
idiopathic RPF patients with a single functioning kidney.
Glucocorticoid administration with or without ureteral
decompression is generally considered the standard treatment
for idiopathic RPF [1,8]. However, there is no guideline con-
cerning the optimal dose of steroid or duration of treatment
for the management of idiopathic RPF. Vaglio et al [9] reported
that prednisone is more effective than tamoxifen in preventing
the recurrence of RPF; in their study, patients received 1 mg/kg
of prednisone daily for 1 month. However, Moulik et al [10]
reported the successful treatment of a case of Riedel's thyr-
oiditis and idiopathic RPF with a modest dose of prednisolone
(30 mg/day). Therefore, we decided to start treatment with a
dose of 30 mg prednisone/day because of the high incidence of
steroid-induced complications [11]. Our patient recovered
without experiencing any side effects of the corticosteroid.
In summary, we successfully treated idiopathic RPF in
association with Hashimoto's thyroiditis in a patient with a
single functioning kidney by corticosteroid therapy and tran-
sient intraureteral stent insertion with a double-J catheter.Conﬂict of interest
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